Dapansutrile (OLT1177®)
Broad spectrum of NLRP3-mediated inflammatory diseases (e.g., Arthritis, Heart Failure, Neurodegenerative)
Key Facts
About Olatec Therapeutics
Olatec Therapeutics is a clinical-stage biotech pioneering the development of oral NLRP3 inhibitors, a novel class of anti-inflammatory therapeutics. Its lead asset, dapansutrile, has demonstrated clinical benefit and a clean safety profile in human studies, targeting conditions from arthritis to heart failure and neurodegenerative diseases. The company boasts a deep pipeline of approximately 40 candidates and a robust intellectual property portfolio of over 180 patents globally. Led by an experienced team with co-founder Damaris Skouras at the helm and scientific luminary Dr. Charles Dinarello guiding R&D, Olatec is positioned to capitalize on the significant unmet need in inflammasome-mediated diseases.
View full company profile